After completing the characterization of the transcriptional and mutational landscape of the various AML subgroups comprised in the leucegene cohort, the team is now orienting towards the identification of small molecules of therapeutic relevance targeting these subgroups.

The team has discovered several therapeutic targets for AML and will shortly initiate the repositioning of a number of clinically available drugs for specific AML subgroups in clinical trial centers.

Characterisation of compounds that emerged from the various screens performed by the team is also underway leading to drug discovery programs to improve the prognostics of poor outcome AML subgroups.